Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APLTNYSE:CPSRNASDAQ:ESPRNASDAQ:URGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$4.74-1.9%$5.75$0.88▼$9.39$501.92M1.811.98 million shs724,360 shsCPSRCapstar Special Purpose Acquisition$6.53$8.28$6.06▼$12.23$225.29M0.07556,189 shs237,378 shsESPREsperion Therapeutics$1.87+1.6%$2.49$0.70▼$3.40$354.18M0.846.80 million shs6.02 million shsURGNUroGen Pharma$14.26+0.1%$16.30$8.69▼$24.13$334.40M1.07343,932 shs315,324 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-6.21%-12.18%-18.96%+93.98%+438.10%CPSRCapstar Special Purpose Acquisition0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics-3.66%-26.98%-10.24%-14.42%+39.39%URGNUroGen Pharma-1.73%+9.96%-1.79%-0.21%+49.42%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.7563 of 5 stars4.53.00.04.72.63.30.6CPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AESPREsperion Therapeutics3.1159 of 5 stars3.22.00.03.91.10.80.6URGNUroGen Pharma4.0057 of 5 stars3.51.00.04.52.43.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics3.00Buy$11.60144.73% UpsideCPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AESPREsperion Therapeutics2.40Hold$9.33399.11% UpsideURGNUroGen Pharma3.00Buy$46.67227.26% UpsideCurrent Analyst RatingsLatest ESPR, APLT, URGN, and CPSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.004/11/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.004/10/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/4/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/25/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/25/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/15/2024URGNUroGen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $34.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$9.99M50.24N/AN/A($0.20) per share-23.70CPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/A($1.18) per shareN/AESPREsperion Therapeutics$116.33M3.04N/AN/A($3.85) per share-0.49URGNUroGen Pharma$82.71M4.04N/AN/A($2.78) per share-5.13Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)CPSRCapstar Special Purpose Acquisition-$15.30MN/A0.00∞N/AN/AN/AN/AN/AESPREsperion Therapeutics-$209.25M-$2.12N/A6.03N/A-179.87%N/A-91.62%5/14/2024 (Estimated)URGNUroGen Pharma-$102.24M-$3.73N/AN/AN/A-123.61%N/A-70.48%5/9/2024 (Estimated)Latest ESPR, APLT, URGN, and CPSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023URGNUroGen Pharma-$0.67-$0.72-$0.05-$0.72$22.30 million$23.53 million 3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) million2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.760.76CPSRCapstar Special Purpose AcquisitionN/A0.130.13ESPREsperion TherapeuticsN/A1.290.87URGNUroGen PharmaN/A5.425.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CPSRCapstar Special Purpose Acquisition64.87%ESPREsperion Therapeutics47.39%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics19.10%CPSRCapstar Special Purpose AcquisitionN/AESPREsperion Therapeutics0.60%URGNUroGen Pharma11.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics25105.89 million85.66 millionOptionableCPSRCapstar Special Purpose Acquisition234.50 millionN/ANot OptionableESPREsperion Therapeutics240189.40 million188.27 millionOptionableURGNUroGen Pharma19823.45 million20.84 millionOptionableESPR, APLT, URGN, and CPSR HeadlinesSourceHeadlineBuy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentationsmarkets.businessinsider.com - April 18 at 12:39 PMUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 18 at 8:23 AMUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancersbusinesswire.com - April 17 at 12:02 PMUroGen's UGN-103 advances to Phase 3 for bladder cancerinvesting.com - April 16 at 10:43 PMUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancerbusinesswire.com - April 15 at 8:00 AMUroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekfinance.yahoo.com - April 14 at 1:17 PMUrogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Ratingmarkets.businessinsider.com - April 4 at 3:29 PMUroGen Pharma (NASDAQ:URGN) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 4 at 8:50 AMUroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stockinsidertrades.com - March 22 at 6:30 AMMark Schoenberg Sells 12,000 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stockmarketbeat.com - March 20 at 7:50 PMUroGen Pharma Ltd. (NASDAQ:URGN) to Post Q1 2025 Earnings of ($0.73) Per Share, HC Wainwright Forecastsmarketbeat.com - March 19 at 7:14 AMUroGen: All Eyes On UGN-102seekingalpha.com - March 18 at 11:48 PMOppenheimer Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $34.00marketbeat.com - March 18 at 6:32 PMUroGen Pharma (NASDAQ:URGN) Rating Reiterated by HC Wainwrightmarketbeat.com - March 18 at 5:32 PMUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 17 at 5:45 PMUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 2:14 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)markets.businessinsider.com - March 14 at 11:32 PMUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finanznachrichten.de - March 14 at 6:32 PMUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challengesfinance.yahoo.com - March 14 at 1:26 PMURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 1:03 PMUrogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 14 at 10:10 AMUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finance.yahoo.com - March 14 at 8:25 AMUroGen Pharma earnings preview: what to expectmarkets.businessinsider.com - March 13 at 12:58 PMUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 8 at 8:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Capstar Special Purpose AcquisitionNYSE:CPSRCapstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.Esperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.UroGen PharmaNASDAQ:URGNUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.